{"product_id":"ateapharma-pestle-analysis","title":"Atea Pharmaceuticals PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how political shifts, regulatory scrutiny, and rapid biotech innovation shape Atea Pharmaceuticals' strategic trajectory—our concise PESTLE snapshot highlights key external risks and opportunities investors and strategists can't ignore. Purchase the full PESTLE analysis for a detailed, ready-to-use briefing that helps you forecast risk, identify growth levers, and make confident decisions—download instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act subjects certain small-molecule drugs to Medicare price negotiations after nine years (or seven for biologics), pressuring oral antiviral pricing; estimates suggest negotiated prices could cut list prices by 20–40%, affecting Atea’s revenue per course projected at $1,200–$3,000. \u003c\/p\u003e\n\u003cp\u003eFor Atea, this creates forecasting uncertainty: with potential federal negotiation applying post-launch, NPV models must include downside scenarios reducing peak sales by 30–50% and margin compression of 10–25%. \u003c\/p\u003e\n\u003cp\u003eStrategic planning must now incorporate timing to market, patent life, and potential alternative pricing strategies—risk-adjusted revenue forecasts and sensitivity analyses are essential given IRA-driven policy risks. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePandemic Preparedness Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment initiatives boosting pandemic preparedness—reflected in the US allocating roughly $88 billion to biodefense in 2024–25 and BARDA’s expanded 2024 budget ~ $2.8 billion—create favorable conditions for antiviral R\u0026amp;D; Atea could access federal grants, development awards, or future stockpiling contracts if its candidates target CDC high-priority pathogens. Maintaining strong BARDA ties remains a strategic imperative for potential contract and milestone revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability and Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConducting global clinical trials requires political stability in host countries to ensure data integrity and patient safety; disruptions in 2024–2025 saw a 12% rise in trial delays tied to geopolitical events per ClinicalTrials.gov analyses.\u003c\/p\u003e\n\u003cp\u003eTensions in Eastern Europe and parts of Asia have already disrupted enrollment and supply chains, contributing to increased logistics costs—sponsor-reported median per-patient costs rose ~8% in 2024.\u003c\/p\u003e\n\u003cp\u003eAtea must diversify trial sites across stable regions; spreading a Phase II\/III program over at least 4–6 countries reduced enrollment risk by ~30% in recent industry case studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Election Regulatory Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing recent US elections, leadership changes at HHS and FDA could reprioritize resources, affecting drug approval timelines—average FDA review times shifted by ±20% in past administration changes, and EUA criteria were tightened in 2022 with a 15% faster revocation rate for viral treatments.\u003c\/p\u003e\n\u003cp\u003eFor Atea Pharmaceuticals, this may alter go\/no-go timing for late-stage assets and cash runway planning given R\u0026amp;D spend of $180m in 2024 and $220m projected for 2025.\u003c\/p\u003e\n\u003cp\u003eManagement must remain agile, updating regulatory scenarios and contingency budgets to mitigate delays and capitalize on expedited pathways.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonitor FDA\/HHS leadership; model ±20% approval timing variance\u003c\/li\u003e\n\u003cli\u003eStress-test cash runway vs R\u0026amp;D spend (2024: $180m; 2025 proj: $220m)\u003c\/li\u003e\n\u003cli\u003ePrepare EUA and full approval contingency plans\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Trade Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpinternational trade agreements like usmca eu pacts and wto rules shape export of apis finished antivirals disruptions can alter cross-border movement regulatory alignment. changes in tariffs global average applied tariff on pharmaceuticals but spikes specific markets raise cogs for clinical-stage firms atea. atea must monitor us-china relations supplier concentration to avoid api shortages margin compression.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonitor tariffs and trade disputes (avg pharma tariff ~2.6% in 2023)\u003c\/li\u003e\n\u003cli\u003eTrack supplier\/geographic concentration for APIs to prevent shortages\u003c\/li\u003e\n\u003cli\u003eAssess cost impact on COGS and margins from tariff changes\u003c\/li\u003e\n\u003cli\u003eAlign logistics with evolving US-China and EU trade policies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pinternational\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIRA cuts risk 20–40% pricing; peak sales -30–50%, stress-test runway vs BARDA upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIRA negotiations may cut antiviral prices 20–40%, risking 30–50% lower peak sales and 10–25% margin compression; include ±20% FDA timing variance and stress-test cash runway (2024 R\u0026amp;D $180m; 2025 proj $220m). BARDA\/biodefense funding (~$2.8bn BARDA; US biodefense ~$88bn 2024–25) offers grant\/stockpile upside. Monitor trade risks (avg pharma tariff ~2.6% 2023) and diversify trial sites.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice cut risk\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak sales downside\u003c\/td\u003e\n\u003ctd\u003e30–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargin compression\u003c\/td\u003e\n\u003ctd\u003e10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBARDA budget\u003c\/td\u003e\n\u003ctd\u003e$2.8bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS biodefense\u003c\/td\u003e\n\u003ctd\u003e$88bn (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$180m (2024); $220m (2025 proj)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg pharma tariff\u003c\/td\u003e\n\u003ctd\u003e2.6% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Atea Pharmaceuticals across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section supported by current data and trends to identify threats and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, shareable PESTLE snapshot for Atea Pharmaceuticals that clarifies regulatory, market, and technological risks for quick alignment in meetings or slide decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Market Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAtea, as a clinical-stage biotech, depends on equity markets to fund R\u0026amp;D; biotech index volatility (Nasdaq Biotechnology Index fell ~28% in 2022 and was ±12% in 2024) can raise cost of capital and force dilutive raises, making access to favorable financing uncertain. Maintaining a cash runway—Atea reported $325M cash equivalents at end-2024—is critical to survive market instability and higher interest-rate environments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising costs for lab supplies, specialized labor and clinical sites have pushed biotech R\u0026amp;D inflation to ~7-9% annually; for Atea this can add millions to a typical Phase II burn (avg. $4–8M\/month), forcing strict cost controls to keep milestones on budget. High inflation erodes payer purchasing power—US healthcare inflation ran ~4.5% in 2024 and global health budgets tightened—risking slower uptake and pricing pressure from government payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe current interest rate environment—US Fed funds target at 5.25–5.50% as of Dec 2024—raises discount rates used to value pre-revenue biotech firms like Atea, increasing weighted average discount rates often by several hundred basis points versus 2020–2021 levels. Higher rates push investors toward revenue-generating biopharma, compressing Atea’s implied valuations and raising the cost of any future debt financing, which could limit strategic flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConducting international clinical trials exposes Atea to FX fluctuations that affected biotech peers in 2024, with emerging-market currencies swinging 8–15% vs USD, potentially altering reported R\u0026amp;D expense by millions when translated.\u003c\/p\u003e\n\u003cp\u003eA stronger US dollar raises local operating costs when converted to Atea’s USD functional currency, as a 10% USD appreciation can effectively increase foreign expenses by ~10% in USD terms.\u003c\/p\u003e\n\u003cp\u003eHedging strategies—forward contracts or FX options—may be necessary to protect cash reserves during large-scale trials; in 2024, 60% of mid-cap biotechs reported active FX hedging to limit volatility risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInternational trial FX exposure: 8–15% currency swings (2024)\u003c\/li\u003e\n\u003cli\u003eUSD appreciation impact: ~10% rise in translated expenses per 10% USD gain\u003c\/li\u003e\n\u003cli\u003eRisk mitigation: 60% of mid-cap biotechs used FX hedging in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Competitiveness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe antiviral market is crowded with Big Pharma—Pfizer, GSK, and Merck—each with billions in R\u0026amp;D and marketing (2024 combined antiviral sales \u0026gt;$40bn), pressuring Atea to differentiate to win share and justify premium pricing.\u003c\/p\u003e\n\u003cp\u003eAtea’s economic case hinges on proving superior efficacy or convenience versus lower-cost incumbents; failing that, market entry risks margin compression and limited uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 antiviral market \u0026gt;$40bn\u003c\/li\u003e\n\u003cli\u003eCompetitors: Pfizer, GSK, Merck with multi‑billion R\u0026amp;D budgets\u003c\/li\u003e\n\u003cli\u003eNeed clinically superior outcomes or convenience to sustain premium pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAtea stares at $325M runway as rising rates, R\u0026amp;D inflation and FX volatility bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAtea faces higher funding costs after biotech volatility (Nasdaq Biotech ±12% in 2024), needs $325M runway (end-2024), R\u0026amp;D inflation ~7–9% raising Phase II burn to $4–8M\/month, Fed rate 5.25–5.50% (Dec 2024) raising discount rates, FX swings 8–15% in emerging markets; 60% mid-cap biotechs hedged FX in 2024; antiviral market \u0026gt;$40bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway\u003c\/td\u003e\n\u003ctd\u003e$325M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D inflation\u003c\/td\u003e\n\u003ctd\u003e7–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX swings\u003c\/td\u003e\n\u003ctd\u003e8–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntiviral market\u003c\/td\u003e\n\u003ctd\u003e$40bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAtea Pharmaceuticals PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Atea Pharmaceuticals PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic decision-making and reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751974416761,"sku":"ateapharma-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ateapharma-pestle-analysis.png?v=1772236585","url":"https:\/\/matrixbcg.com\/products\/ateapharma-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}